Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878524 · ClinicalTrials.gov registry record · Phase 1
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
A Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03878524 is a Phase 1 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT03878524, a Phase 1 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
Interventions
- DRUG Abemaciclib
- DRUG Abiraterone
- DRUG Afatinib
- BIOLOGICAL Bevacizumab
- DRUG Bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2020-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878524
The ClinicalTrials.gov registry entry for NCT03878524 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Abemaciclib is the first listed.
NCT03878524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03878524 about?
NCT03878524 is a clinical study titled "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial". This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different peo...
What is the current status of trial NCT03878524?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2020-04-01. Estimated completion is 2020-12-10.
What interventions are being tested in trial NCT03878524?
The interventions under investigation include: Abemaciclib (DRUG), Abiraterone (DRUG), Afatinib (DRUG), Bevacizumab (BIOLOGICAL), Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT03878524?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.